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Abstract
Hemoglobin is a highly reactive molecule, and besides its oxygen-carrying capacity, it has multiple
enzymatic and ligand-binding activities that have only recently been explored as fundamental
pathophysiologic mechanisms. Nitric oxide neutralization, generation of potentially toxic radical
species, and heme-mediated inflammation are among the most extensively studied mechanisms of
Hb-mediated pathology. Extracellular Hb has an established role in sickle cell disease and other
hemolytic disorders. However, extracellular Hb seems also to have relevant disease-modifying activities
in many other important pathologic conditions, such as malaria and atherosclerosis. In this Forum, we
summarize the current knowledge of mechanisms of Hb toxicity. Special emphasis is given to the highly
efficient endogenous scavenger and detoxification pathways, such as alpha-hemoglobin stabilizing
protein (AHSP), haptoglobin, hemopexin, CD163, and heme oxygenase. Systemic and local activity of
these pathways finally determines the impact of extracellular Hb on physiology and tissue homeostasis.
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Multiple physiologic and pathologic conditions areassociated with red blood cell (RBC) lysis and re-
lease of hemoglobin (Hb) into extracellular compartments.
Hemoglobin is a highly reactive molecule, and besides its
oxygen-carrying capacity, it has multiple enzymatic and
ligand-binding activities that haveonly recently been explored
as fundamental pathophysiologic mechanisms (1). The most
paradigmatic condition associated with intravascular free Hb
exposure is hemolysis in sickle cell disease, and therefore,
many disease processes such as Hb-associated systemic
and pulmonary hypertension, vasculopathy, and Hb=heme-
triggered inflammation have initially been explored in the
context of this genetic disorder (8). However, several other
diseases and conditions have been described to be Hb-related
pathologies. The most severe form of malaria, cerebral ma-
laria, has very distinct links to cell-free Hb and heme re-
activities (7). Atherosclerosis with intraplaque hemorrhage
serves as another potentially important example of how ex-
tracellular Hb could worsen disease processes within oxida-
tive and inflammatory susceptible tissues (3, 13). Finally,
experiences with hemoglobin-based oxygen carriers (HBOCs)
are potentially the most extensive source of preclinical and
clinical information on the extracellular effects of Hb within
the vascular and tissue compartments (6).
Although the understanding of the precise mechanisms of
Hb toxicity has considerably expanded, other research has
explored effective physiologic systems that control the ad-
verse activities of Hb from early erythropoiesis to heme
degradation in macrophages. It is an intriguing and conceiv-
able idea that these Hb ‘‘detoxification systems’’ have allowed
the evolutionary success of heme-globin–based oxygen
transport (Fig. 1).
A precise understanding of the molecular processes un-
derlying Hb-mediated pathology will be instrumental in
finally defining valid strategies to control Hb-mediated dis-
eases. The unmet need for effective therapeutic strategies in
hemoglobin-related pathology was just emphasized by the
disappointing news from a failed clinical trial that investi-
gated a nitric oxide (NO)-modulating strategy in sickle cell
disease (see http:==public.nhlbi.nih.gov=newsroom=home=
GetPressRelease.aspx?id¼2650). In this Forum, we summa-
rize the current knowledge about Hb toxicity, together with
an in-depth overview of the most recent understanding of Hb
scavenging and detoxification pathways.
In the first review, Buehler and D’Agnillo give a biochem-
ical and physiological perspective on the known consequences
of extracellular Hb on eukaryotic physiology. A decisive idea
raised in this article is that Hb toxicity is a multifactorial pro-
cess that cannot simply be traced back to nitric oxide (NO)
inactivation (that is the most extensively studied mechanism)
or any other single reaction. Rather, NO neutralization, heme
release, and heme-driven oxidative processes interact with
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other factors to yield the full physiological mosaic of Hb-
associated adverse effects. Maladaptive (damaging) and
adaptive (protective) responses to extracellular Hb and heme,
respectively, can now be impressively reproduced in novel
animal models of human disease, such as the transgenic sickle
cell mice. In their article, Belcher et al. discuss the complex
sequence of extracellular Hb=heme accumulation, oxidant
exposure, inflammation, and vascular damage in the context
of sickle cell disease vascular pathology.
Oxidative control of Hb or its subunits is essential not only
after erythrocyte destruction and extracellular Hb accumula-
tion. It is equally important to control redox activity and
the structural integrity of single a-globin chains before they
assemble to form tetrameric (a2b2) hemoglobin during ery-
thropoesis. Mollan et al. explain the essential role of the evo-
lutionarily conserved a-hemoglobin-stabilizing protein (AHSP)
in fine tuning RBC precursor maturation. As a chaperone,
AHSP rapidly captures newly synthesized Hb a-globin chains
within a low-affinity a-globin: AHSP complex. AHSP supports
a-globin folding, controls oxidative chemistry at its heme
group, and prevents a-subunit precipitation. Subsequently,
AHSP allows tetrameric Hb formation by slowly releasing
bound subunits into the higher-affinity ab–globin interaction.
A series of reviews summarizes the major physiologic
scavenger pathways that exist to detoxify and clear Hb when
it is released from bursting RBCs. Haptoglobin (Hp) is a
plasma glycoprotein with a genetically determined dimeric
or multimeric structural assembly (a2b2 . . . axbx). Each Hp
b-subunit can bind one Hb dimer with an extremely high
affinity to form an irreversible and high-molecular-weight
Hb:Hp protein complex. Although Hp was identified as the
primary plasmatic Hb scavenger in the early days of physio-
logical biochemistry, some essential functions of this molecule
have been explored only recently. However, it is now recog-
nized that Hp has the potential to attenuate some of the major
adverse effects of Hb, such as vasoactivity, oxidative tissue
damage, and peroxidative self-destruction of the Hb heme
and globin moieties (2, 4). Although Hp drastically changes
the physiologic effects of Hb in vivo, the ligand-binding and
enzymatic properties at its heme sites remain preserved (2).
Therefore, the unaltered kinetics of heme-based reactions
within the complex suggest distinct functions of Hb:Hp dur-
ing hemoylsis, inflammation, or wound healing. Wicher et al.
review the evolutionary framework of Hb and heme scaven-
gers. Haptoglobin first appeared in bony fish. There, the
protein gained its high-affinity Hb-binding function from an
ancient innate immunity protease. Later, other Hb-binding
proteins, such as the SRCR proteins CD163 and pit54, ap-
peared; these originated from a completely different cysteine-
rich protein family. The result of these evolutionary events is a
redundant and highly regulated system of soluble capture
proteins and cellular receptors that effectively shield mam-
malian species from Hb-related damage (10).
Although Hp is generally considered to have protective
activities, the polymorphic Hp phenotype (Hp 2-2) is linked to
a higher incidence of oxidative stress–associated diseases,
such as micro- and macrovascular complications in diabetes
patients. In the future, this genotype–disease relation might
offer the possibility to identify a high-risk (Hp 2-2) population
of patients deserving personalized prevention or treatment
FIG. 1. Schematic representation of compartmentalized hemoglobin toxicity, scavenger proteins, and detoxification
pathways.
182 SCHAER AND ALAYASH
strategies or both. Distinct differences between the dimeric
Hp 1-1 and multimeric Hp 2-2 in respect to their capability to
control Hb-mediated peroxidative processes could be the
basis for these clinical observations and may form the ratio-
nale for targeted treatment interventions. These basic and
clinical aspects of Hp and its unique polymorphism are re-
viewed in the article by Levy et al.
After depletion of Hp and with oxidation of the heme iron,
heme eventually dissociates from globin. Hempoexin (Hpx) is
the primary scavenger for free heme that backs up the plasma
Hb-binding capacity provided by haptoglobin. The physio-
logic role of hemopexin was highlighted in Hp=Hpx double-
knockout mice that are prone to severe liver inflammation,
splenomegaly, and oxidative endothelial damage (12). Like
cell-free Hb, heme sequestered within hemopexin is cleared
from the circulation and from heme-exposed tissues by a
dedicated receptor-clearance pathway (CD91=LRP). In addi-
tion to heme-binding, other biologic functions of hemopexin
involve regulatory functions in cell signaling and cell survival.
The diverse facets of this multifunctional plasma protein are
summarized in the article by Tolosano et al. The Hb:Hp and
heme:Hpx complexes are finally cleared by their respective
endocytosis receptors CD163 and CD91=LRP before they are
degraded by lysosomal proteases. Nielsen et al. review our
current knowledge about the molecular function of these
carrier protein–dependent receptor systems and how activa-
tion of downstreammetabolic pathways can link toxic heme=
Hb exposure to antioxidant and antiinflammatory cellular
responses (9).
Three original contributions close this Forum. Butt et al.
show that significant species differences exist in the redox
status of extracellular Hb that is secreted through the kidney.
The significant interspecies differences that exist in important
antioxidant systems (i.e., extensive ascorbate synthesis in rats
but not in guinea pigs) are a potential explanation for these
findings and may also in part explain the role of ascorbate in
variable adaptive ferritin synthesis. These data support the
concept of appropriate animal species and models in the in-
vestigation of Hb-related pathology. Asleh et al. investigated
the intriguingly opposing effects of the two antioxidants,
ascorbic acid and a-tocopherol on Hb-driven HDL peroxi-
dation. The results presented in their article can help us
to understand the pharmacogenomic interactions of Hb,
Hp phenotypes, and different antioxidant strategies in
atherosclerosis-prone individuals. In the final article of this
Forum, Widmer et al. add a provocative novel facet to the
complex biology of extracellular Hb. Although the H2O2-
degrading (peroxidase) activity of Hb has been known for
decades, this activity was largely considered destructive
because the radicals produced in the peroxidase reaction of
Hb–H2O2 could damage circulating biomolecules and tissues.
With a complementary repertoire of cell-biology assays, com-
prehensive gene-expression analysis, and biochemical meth-
ods, Widmer et al. showed that Hb has the potential to absorb
a significant amount of oxidative impact within its peptide
structure. This self-destructive process involves amino acid
oxidation, globin chain cross-linking, and finally precipitation
of the altered protein (5, 11). Thereby, extracellular Hb acts as a
protective peroxidase that can attenuate H2O2-mediated
oxidative stress and preserve cellular viability during H2O2
exposure. These observations strongly imply that extracellular
Hb could be a double-edged sword with both damaging and
protective effects on tissue homeostasis, similar to those of
H2O2. The net physiologic impact is likely dependent on spe-
cific environmental factors, such as the presence of Hp or the
level of macrophage CD163 expression.
We hope that the series of reviews and original contribu-
tions collected in this Forum will provide a comprehensive
source of knowledge and stimuli for the growing community
of researchers and clinicians involved in the fascinating field
of hemoglobin-related pathology.
Author Disclosure Statement
No conflict of interest exists. The findings and conclusions
in this article have not been formally disseminated by the
Food and Drug Administration and should not be construed
to represent any agency determination or policy.
Acknowledgments
The research of D.J.S. is supported by the Swiss National
Science Foundation grant 31-120658 and by the Fonds fu¨r
Akademische Nachwuchsfo¨rderung (FAN), Zurich.
References
1. Alayash AI. Oxygen therapeutics: can we tame haemoglo-
bin? Nat Rev Drug Discov 3: 152–159, 2004.
2. Boretti FS, Buehler PW, D’Agnillo F, Kluge K, Glaus T, Butt
OI, Jia Y, Goede J, Pereira CP, Maggiorini M, Schoedon G,
Alayash AI, and Schaer DJ. Sequestration of extracellular he-
moglobin within a haptoglobin complex decreases its hyper-
tensive and oxidative effects in dogs and guinea pigs. J Clin
Invest 119: 2271–2280, 2009.
3. Boyle JJ, Harrington HA, Piper E, Elderfield K, Stark J,
Landis RC, and Haskard DO. Coronary intraplaque hemor-
rhage evokes a novel atheroprotective macrophage pheno-
type. Am J Pathol 174: 1097–1108, 2009.
4. Buehler PW, Abraham B, Vallelian F, Linnemayr C, Pereira
CP, Cipollo JF, Jia Y, Mikolajczyk M, Boretti FS, Schoedon G,
Alayash AI, and Schaer DJ. Haptoglobin preserves the
CD163 hemoglobin scavenger pathway by shielding hemo-
globin from peroxidative modification. Blood 113: 2578–2586,
2009.
5. Jia Y, Buehler PW, Boykins RA, Venable RM, and Alayash
AI. Structural basis of peroxide-mediated changes in human
hemoglobin: a novel oxidative pathway. J Biol Chem 282:
4894–4907, 2007.
6. Natanson C, Kern SJ, Lurie P, Banks SM, and Wolfe SM.
Cell-free hemoglobin-based blood substitutes and risk of
myocardial infarction and death: a meta-analysis. JAMA 299:
2304–2312, 2008.
7. Pamplona A, Hanscheid T, Epiphanio S, Mota MM,
and Vigario AM. Cerebral malaria and the hemolysis=
methemoglobin=heme hypothesis: shedding new light on an
old disease. Int J Biochem Cell Biol 41: 711–716, 2009.
8. Rother RP, Bell L, Hillmen P, and Gladwin MT. The clinical
sequelae of intravascular hemolysis and extracellular plasma
hemoglobin: a novel mechanism of human disease. JAMA
293: 1653–1662, 2005.
9. Schaer CA, Schoedon G, Imhof A, Kurrer MO, and Schaer
DJ. Constitutive endocytosis of CD163 mediates hemoglobin-
heme uptake and determines the noninflammatory and
protective transcriptional response of macrophages to
hemoglobin. Circ Res 99: 943–950, 2006.
Hb CLEARANCE AND CONTROL 183
10. Schaer DJ, Alayash AI, and Buehler PW. Gating the radical
hemoglobin to macrophages: the anti-inflammatory role of
CD163, a scavenger receptor. Antioxid Redox Signal 9: 991–
999, 2007.
11. Vallelian F, Pimenova T, Pereira CP, Abraham B, Miko-
lajczyk MG, Schoedon G, Zenobi R, Alayash AI, Buehler
PW, and Schaer DJ. The reaction of hydrogen peroxide with
hemoglobin induces extensive alpha-globin crosslinking and
impairs the interaction of hemoglobin with endogenous
scavenger pathways. Free Radic Biol Med 45: 1150–1158, 2008.
12. Vinchi F, Gastaldi S, Silengo L, Altruda F, and Tolosano E.
Hemopexin prevents endothelial damage and liver conges-
tion in a mouse model of heme overload. Am J Pathol 173:
289–299, 2008.
13. Yunoki K, Naruko T, Komatsu R, Ehara S, Shirai N, Sugioka
K, Nakagawa M, Kitabayashi C, Ikura Y, Itoh A, Kusano K,
Ohe T, Haze K, Becker AE, and Ueda M. Enhanced ex-
pression of haemoglobin scavenger receptor in accumulated
macrophages of culprit lesions in acute coronary syndromes.
Eur Heart J 30: 1844–1852, 2009.
Address correspondence to:
Dominik Schaer
Division of Internal Medicine
University Hospital
CH-8091 Zurich
Switzerland
E-mail: dominik.schaer@hotmail.com
Date of first submission to ARS Central, September 25, 2009;
date of final revised submission, September 25, 2009; date of
acceptance, September 25, 2009.
184 SCHAER AND ALAYASH
